NasdaqGS - Delayed Quote
USD
REGENXBIO Inc. (RGNX)
5.65
-0.07
(-1.22%)
At close: 4:00:00 PM EDT
5.59
-0.06
(-1.08%)
After hours: 4:32:08 PM EDT
Trade RGNX on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for RGNX
- Previous Close
5.72 - Open
5.70 - Bid 5.61 x 400
- Ask 5.67 x 400
- Day's Range
5.46 - 5.83 - 52 Week Range
5.46 - 16.19 - Volume
2,575,865 - Avg. Volume
1,047,354 - Market Cap (intraday)
292.092M - Beta (5Y Monthly) 1.12
- PE Ratio (TTM)
-- - EPS (TTM)
-5.60 - Earnings Date (est.) Aug 6, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
24.18
Recent News: RGNX
View More
Performance Overview: RGNX
Trailing total returns as of 5/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
RGNX
60.76%
S&P 500 (^GSPC)
8.14%
1-Year Return
RGNX
36.45%
S&P 500 (^GSPC)
24.25%
3-Year Return
RGNX
69.56%
S&P 500 (^GSPC)
76.34%
5-Year Return
RGNX
84.06%
S&P 500 (^GSPC)
79.34%
Earnings Trends: RGNX
View MoreAnalyst Insights: RGNX
View MoreStatistics: RGNX
View MoreValuation Measures
As of 5/8/2026
-
Market Cap
544.56M
-
Enterprise Value
387.99M
-
Trailing P/E
--
-
Forward P/E
--
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
3.19
-
Price/Book (mrq)
5.30
-
Enterprise Value/Revenue
2.28
-
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
-
Profit Margin
0.00%
-
Return on Assets (ttm)
-38.53%
-
Return on Equity (ttm)
-196.43%
-
Revenue (ttm)
87.82M
-
Net Income Avi to Common (ttm)
-290.01M
-
Diluted EPS (ttm)
-5.60
Balance Sheet and Cash Flow
-
Total Cash (mrq)
150.49M
-
Total Debt/Equity (mrq)
1,178.24%
-
Levered Free Cash Flow (ttm)
-138.98M
Compare To: RGNX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: RGNX
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports: RGNX
View More-
Lowering target price to $8.00
REGENXBIO INC has an Investment Rating of HOLD; a target price of $8.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target -
Rating increased to a HOLD
REGENXBIO INC has an Investment Rating of HOLD; a target price of $9.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target -
Raising target price to $8.00
REGENXBIO INC has an Investment Rating of SELL; a target price of $8.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target -
Lowering target price to $7.00
REGENXBIO INC has an Investment Rating of SELL; a target price of $7.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice Target
